Day: August 2, 2022

TORONTO, Aug. 02, 2022 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the three and six months ended June 30, 2022. Management commentary “Assets Under Management (“AUM”) were $21.9 billion as at June 30, 2022, down $1.7 billion (7%) from March 31, 2022 and up $1.5 billion (7%) from December 31, 2021. While our AUM was negatively impacted on both a three and six months ended basis by market value depreciation across our fund products, we are pleased to have maintained strong sales momentum, reporting approximately $0.8 billion in net sales during the second quarter, and $2.2 billion in net sales for the first half of 2022,” said Whitney George, CEO of Sprott. “Our resilient business model allows us to invest through the cycles irrespective of market conditions....

THE WOODLANDS, Texas, Aug. 02, 2022 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the second quarter 2022 and the six months ended June 30, 2022. Second Quarter 2022 Highlights and Comparisons to Second Quarter 2021Net Income increased 4.4% to $123.4 million, or $5.24 Basic EPS and $5.20 Diluted EPS Net Income Before Income Taxes increased 9.3% to $163.0 million Home Sales Revenues decreased 8.6% to $723.1 million Home Closings decreased 29.0% to 2,027 homes closed Average Sales Price increased 28.7% to $356,719 Gross Margin as a Percentage of Homes Sales Revenues increased 500 basis points to 32.0% Adjusted Gross Margin* as a Percentage of Home Sales Revenues increased 460 basis points to 33.1% Active Selling Communities at June 30, 2022 of 92Six Months Ended June 30, 2022 Highlights...

Second Quarter Revenues from Continuing Operations Totaled $481 Million, An Increase of 3% Percent Over Prior-Year Quarter Q2 GAAP Operating Loss from Continuing Operations of $97 Million, Including a Non-Cash Goodwill Impairment Charge of $105 Million Adjusted EBITDA in Q2 Totaled $49 Million Q2 GAAP Loss Per Share of $1.34 and Q2 Adjusted Earnings Per Share of $0.01 Profit Improvement Plan of $30+ Million (in Second Half) Implemented at Clean Earth to Strengthen Performance in Response to Extraordinary Inflation Full Year 2022 Adjusted EBITDA Guidance Range of $210 Million to $220 Million; Free Cash Flow is Now Projected to be Between $115 Million and $125 MillionCAMP HILL, Pa., Aug. 02, 2022 (GLOBE NEWSWIRE) — Harsco Corporation (NYSE: HSC) today reported second quarter 2022 results. On a U.S. GAAP (“GAAP”) basis,...

VANCOUVER, British Columbia, Aug. 02, 2022 (GLOBE NEWSWIRE) — American Lithium Corp. (“American Lithium” or the “Company”) (TSX-V:LI | OTCQB:LIACF | Frankfurt:5LA1) is pleased to report its operating and financial results for the three month period ending May 31, 2022. Unless otherwise stated, all amounts presented are in Canadian dollars. “Q1 of the Company’s financial year was extremely busy with the ramp up in drilling and the launch of the final phase of work needed to complete the maiden PEA at our TLC Project in Nevada (“TLC”),” stated Simon Clarke, CEO of American Lithium. “Additionally, we have generated good momentum on all our projects in the last couple of months. In particular, pre-feasibility work is underway at Falchani and process work has validated Sulfate of Potash (“SOP”) as a key strategic by-product. At Macusani,...

Second Quarter Revenue Increased 21.8% to $178.0 Million Compared to Prior Year Period; Increased 29.7% to $189.6 Million in Constant Currency Updates Fiscal Year 2022 Outlook MALMÖ, Sweden, Aug. 02, 2022 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”), the world’s original and largest oat drink company, today announced financial results for the second quarter and six months ended June 30, 2022. Toni Petersson, Oatly’s CEO, commented, “We delivered strong second quarter financial results with sales growth of 22%, or 30% in constant currency, despite several headwinds including COVID-19 lockdowns in China. Profitability metrics improved compared to the first quarter of 2022 and we expect this trend to continue in the second half of the year. As we expand and scale our more localized production footprint...

— Received FDA approval for IMCIVREE® (setmelanotide) as the first-ever therapy for patients with Bardet-Biedl syndrome — — U.S. launch off to a strong start with more than 50 IMCIVREE prescriptions written for patients with BBS in first six weeks since FDA approval — — EMA’s CHMP recommended expansion of IMCIVREE marketing authorization to include treatment of obesity and control of hunger in patients with genetically confirmed BBS; EC approval anticipated in the fourth quarter of 2022 — — Announced positive interim results from Phase 2 trial in hypothalamic obesity and plans to initiate Phase 3 trial in early 2023 — — Entered into non-dilutive revenue interest financing agreement with Healthcare Royalty Partners for up to $100 million, extending cash runway into second half of 2024...

– Achieved 100% of Targeted MACE-4 Accumulation in Unprecedented CLEAR Outcomes Trial; On Track for Topline Results 1Q 2023 – – U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets grew 28% Y/Y to $13.6 Million in the Second Quarter 2022 – – Retail Prescription Equivalents Grew 5.9% Quarter over Quarter – ANN ARBOR, Mich., Aug. 02, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today reported financial results for the second quarter ended June 30, 2022 and provided a business update. “Throughout the second quarter of 2022, we have continued to demonstrate consistent growth and we have made significant progress in advancing our unprecedented CLEAR Outcomes trial, which has now reached 100% MACE accumulation,” said Sheldon Koenig, president and chief executive officer...

CHARLOTTE, N.C., Aug. 02, 2022 (GLOBE NEWSWIRE) — Glatfelter Corporation (NYSE: GLT), a leading global supplier of engineered materials, today reported a loss from continuing operations for the second quarter of 2022 of $2.5 million, or $0.05 per share, compared with net income of $1.5 million, or $0.03 per share, in the same period a year ago. On an adjusted basis, earnings from continuing operations for the second quarter of 2022 and 2021 were a loss of $1.6 million, or $0.04 per share, compared with adjusted earnings of $8.0 million, or $0.18 per share, respectively. Adjusted earnings is a non-GAAP financial measure for which a reconciliation to the nearest GAAP-based measure is provided within this release. The 2021 results include the acquisitions of Georgia-Pacific’s U.S. nonwovens business (“Mount Holly”) and Jacob Holm...

SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis, today reported financial results for the second quarter ended June 30, 2022. Recent HighlightsReported total operating expenses for the second quarter of 2022 of $15.5 million, down sequentially from $16.0 million in the first quarter of 2022 and from $16.8 million in the fourth quarter of 2021. Announced the hiring of industry veterans Eric Spence and Ken Kuhn as VP of Instrument Engineering and VP of Reagent and Process Development, respectively, to strengthen Nautilus’ development efforts. Provided guidance that anticipates the launch of the Nautilus proteome analysis platform – instruments and reagents – by mid-2024 with meaningful early access engagements...